Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
Sign Up to like & getrecommendations! Published in 2020 at "Drug Safety"
DOI: 10.1007/s40264-020-00938-z
Abstract: The introduction of novel, small-molecule Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics. This review aimed to… read more here.
Keywords: baricitinib; tofacitinib baricitinib; drug; baricitinib upadacitinib ... See more keywords